INSULIN-RESISTANCE-IMPROVING DRUG

• US 20130156793A1
• Filed: 05/27/2011
• Published: 06/20/2013
• Est. Priority Date: 05/27/2010
• Status: Active Grant

• Current Assignee: Kohjiro Ueki, Takashi Kadowaki
• Original Assignee: Sekisui Medical Company Limited (Sekisui), University of Tokyo
• Inventors: Kadowaki, Takashi, Bluher, Matthias, Ueki, Kohjiro, Okazaki, Yukiko, Ozawa, Sumiko
• Granted Patent: US 8,895,011 B2
• Time in Patent Office: Days
• US Class Current: 424/172.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/7125 Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Provided are a means for the prevention and treatment of obesity and/or insulin resistance and, particularly, pharmaceutical drugs for the treatment of obesity and/or insulin resistance under the influence of FSTL3. Specifically, provided is an insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient, particularly, the insulin resistance improving drug, wherein the FSTL3 inhibitor is one of (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3, (B) an inhibitor for expression of FSTL3, and (C) a competitor of FSTL3.

Claims

1. An insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient.

2. The insulin resistance improving drug according to claim 1, wherein

the FSTL3 inhibitor is any one of:

(A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3;

(B) an inhibitor for expression of FSTL3; and

(C) a competitor of FSTL3.

3. An insulin resistance improving drug comprising (A), (B), or (C) of claim 2 and a pharmaceutically acceptable diluent or carrier.

4. Use of one or more of (A), (B), and (C) of claim 2 in the manufacture of a medicament for inhibiting FSTL3.

5. Use of one or more of (A), (B), and (C) of claim 2 in the manufacture of a composition used for a treatment of insulin resistance in animal or human.

7. The insulin resistance improving drug according to claim 2, wherein the (A) substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3 is an antibody.

8. The insulin resistance improving drug according to claim 2, wherein the (A) substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3 is activin A, activin B, or activin AB.

9. The insulin resistance improving drug of claim 2, wherein the (B) inhibitor for expression of FSTL3 is an antisense oligonucleotide.

6. A method of screening a compound for preventing or treating obesity or insulin resistance comprising the steps of:

(1) bringing a test compound into contact with FSTL3-expressing cells; and

(2) confirming whether the test compound improves inhibition of signal transduction due to FSTL3.

10. A method for improving insulin resistance comprising:

the step of administering an FSTL3 inhibitor.